The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice

AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) receptor agonists are currently used for the treatment of type 2 diabetes. Their main mechanism of action is enhancement of glucose-induced insulin secretion (from increased beta cell glucose sensitivity) and inhibition of glucagon secretion. The latt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ørgaard, Anne, Holst, Jens J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552842/
https://www.ncbi.nlm.nih.gov/pubmed/28551699
http://dx.doi.org/10.1007/s00125-017-4315-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552842/
https://www.ncbi.nlm.nih.gov/pubmed/28551699
http://dx.doi.org/10.1007/s00125-017-4315-2

Ejemplares similares